dCas9 Synergistic Activation Mediator Lentivirus
Cat. No.
K016
Unit
4 x 500ul
Price
$350.00
| Cat. No. | K016 |
| Name | dCas9 Synergistic Activation Mediator Lentivirus |
| Unit | 4 x 500ul |
| Description |
This Cas9 Double Mutant (dCas9) has changes at amino acid positions D10A and H840A which completely inactivate both the nuclease and nickase activities. With a target-specific guide RNA (sgRNA), it can bind to a specific region of DNA without cutting it. In this construct, dCas9 carries a C-terminal tripartite synergistic activation mediator (SAM). By targeting dCas9-SAM to a promoter region, users will be able to specifically induce expression of virtually any gene of interest. |
| Vector | pLenti-EF1a-dCas9-SAM |
| Titer | 107 IU/mL |
Print & Download Datasheet
Search CoA here
There are no Documents for this product yet!
| How long after transduction can the infection efficiency be observed? | |
|
You can observe transduction efficiency from 48 hours up to 5 days after infection.
|
| What are the primers to use for SV40T and SV40T tsA58 detection? | |
|
PCR primers:
SV40T Forward Primer Sequence
5’ AGCCTGTAGAACCAAACATT 3'
SV40T Reverse Primer Sequence
5’ CTGCTGACTCTCAACATTCT 3'
The two primers should amplify the region between 3677-4468bp, giving a 792bp fragment.
|
| What is the sequence of the SV40 large T antigen? | |
|
This information can be accessed on this page by clicking on "pLenti-SV40-T" under vector map. The Large T antigen is at position 5079-5927.
|
| What system is your dCas9-SAM? | |
|
Our dCas9-SAM is the VPR version (i.e. dCas9-VPR).
|
| For G221 and LV620, what does the 'V12' in RasV12 mean? | |
|
The V12 means that amino acid # 12 is mutated from a Valine to a Glycine. Other than that, the sequence matches the coding region of HRAS perfectly (NM_005343).
|
| Where is the SV40T tsA58 gene sequence? | |
|
The SV40T tsA58 gene is located between 3138-5264bp, with the Alanine-to-Valine mutation at amino acid 438.
|
There are no references for this product yet!
This product has no review yet.
